And then I’ll have a couple of follow ups.
Joseph H. Capper: Thanks, Anthony. Well, first of all, we really don’t know because they never pulled back curtain and let you know why they made the decision that they made. If you’re asking me for my personal opinion, I never thought I had a chance of being implemented. Because I thought it was arbitrary and completion, quite frankly. And, there was no good evidence to support the four application cap, and it was I think the flimsy evidence to support the restriction on some of the products and organizations that were eliminated for participating. But, you asked me, I think we’re maybe trying to make up since for the past. But any case, I’ll just – we’ll never really know. I think it was probably more the, uproar across the industry, both clinically and from, industry that this was, not a great way to approach the problem that they’re trying to solve.
And they indicated that they would continue to analyze and collect more evidence and try to see if there’s a better way to approach these LCDs in the future. So, as I indicated in my commentary, we continue to work with various stakeholders who have an influence on this. We would — we continue to advocate for policy that would, eliminate some of the gamesmanship that’s permitted around reimbursement of these products at the same time maintaining access for, products like ours that have tremendous evidence that show effectiveness. So I do I think something will change at some point in the future? Yes. Do I know what it is? Absolutely not. I would say though that of all the companies in the category, we are — I believe, far and away best positioned to continue to support the private office setting regardless of the change.
If it moved, into some sort of, restricted utilization, we have evidence to support use of our product. If, for some reason, it moves towards a bundle, we have probably less impact than some of our other large competitors in category. So look, we’re going to continue to support this sector. We think it makes a lot of sense. It’s great access for patients that can’t necessarily be treated in the hospital, and it continues to grow as a result. So, again, I think we’re just really well positioned regardless of the outcome, but we’ll continue to try to influence it.
Anthony Petrone: That’s very helpful. And then maybe just two nuances in there. I mean, one was the, you know, advocacy and push from my medics that all of these products be, sort of, disclosed on the Medicare B pricing list as opposed to wholesale acquisition cost. And then there was another, decision in these LCDs where they actually wanted to limit applications to four for ulcer, which was below the 10 applications previously. So maybe just on those two specifically, I mean, is there anything that my medics is aware of on those two levers versus certainly going to Medicare Part B is positive for EPIFIX and other products that were included in the 58. On the other hand limiting the applications per ulcer just seemed like perhaps too limiting. Is there anything on those two levers you can share?
Joseph H. Capper: No, not really. Again we continue to work with them and hopefully this gets clouds part over time. We get more clarity. We’ve always — we thought that the application restriction was somewhat arbitrary. There was a good point of some evidence, but it was misconstrued in the way that it’s being applied. So hopefully that goes away because that could be disruptive for patients that need more than four applications or they, they end up going into a more expensive care setting, excuse me, care setting frankly to get treated. So it’s not really good for Medicare long term. As far as continuing influence the use of the ASP versus the WACC, we think that’s the easiest way to go in the near term, its kind of the low hanging fruit.
And to their credit, the CMS has been pressuring people to move in that direction. As you know, the OIG published a letter earlier in the year, pretty much directing them to adhere to these guidelines. And we have seen a lot of products move on the ASP price cuts. If you looked at the list a couple of years ago, there was maybe 12 products on the list, and now it’s probably up to around 75. So the market is moving in the right direction. And quite frankly, that could be one of the reasons we performed so well, in that site of service for the first three quarters of the year, because the fine field is starting to level a bit.
Anthony Petrone: Last one, and I’ll hop in real quick. Just on EBITDA, second half, all three, to exceed 20%. Maybe just high level, there was restructuring program earlier this year to help in achieving that 20%. As you as you look forward next couple of years, how much of the EBITDA expansion will just be from organic growth as opposed to a follow on restructuring program. Congratulations again. Thanks.
Doug Rice: Thanks, Anthony. This is Doug. I’ll take your question. We’re excited exiting the year with a lot of momentum. We had a really solid strong Q3. We saw improved execution that will continue into Q4, and now with the new product introduction, we’re going to have a lot of upside and growth it’ll help us scale. We expect our gross margin stands back up from an EBITDA perspective. We also expect to scale in sales and marketing and realize efficiencies all along our P&L. So, as our crew focus, as you mentioned, from the suspension of our [DOA] (ph) program, helps going into next year. We feel like we have a lot of momentum and ability to continue to grow into the double digits.
Anthony Petrone: Thanks again.
Joseph H. Capper: And Anthony, the only other thing I might add, is just some of those legacy expenses kind of across the board. There’s focus. There’s SG&A leverage. There’s obviously, kind of get a sense of where the R&D trend line looks and then obviously not having any other ancillary pieces hitting us, whether we adjust them or not should show a really nice kind of leveraged P&L.
Anthony Petrone: Thanks again.
Joseph H. Capper: Thank you.
Operator: Thank you. Our next question comes from the line of Carl Byrnes with Northland Capital Markets. Please proceed with your question.
Carl Byrnes: Thanks for the question and congratulations on your quarter and the progress here. I think most of my questions have been addressed. But as a bit curious, if you see an opportunity for further purchases in the Series B preferred, such that it’s done and organized in orderly fashion. And then I have a follow-up to that. Thank you.
